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Abstract In COPD, severalwalking tests have beenproposed tomeasure exercise tolerance buttheir relativemerits
are uncertain.We studied 57 moderate-to-severe, stable COPD patients (mean FEV135712% predicted).Within a 2-
month period, we compared reliability (inter-subject variability) and repeatability (intra-subject variability) of themost
widely used 6-min walks (6MWD), with self-paced 2-min walks (2MWD) and externally paced, incremental shuttles
(Shuttle).On 9 separate days either of the three 6MWD, 2MWD or Shuttles were performed (nine walks of each type).
Then, each walk was performed before and after bronchodilators (BD) to assess sensitivity to change (mean change/
standard deviation of change (sensitivity indexF SI)).For all exercise tests, reliability was490% (2MWD 95%,6MWD
92% and Shuttle 91%).Repeatabilitywas excellent (overallol0% intra-subject variation; for 2MWD 5%,6MWD 8% and
Shuttle 9%).On average, the first walking distance was significantly shorter, but there were no significant differences
betweensecondandthirdwalks.Dyspnoea scoresweremuchlessreproducible.BDproducedhighlysignificantimprove-
ments in Shuttle (pre-BD 27 SD =11-post-BD 30 SD=11), 6MWD (424m SD=115-462m SD=106) and 2MWD (153m
SD=35-162m SD=34), (Po0.000l). SIwas similar for allwalks (6MWD 0.84, 2MWD 0.75 and Shuttle 0.76). Inmoderate-
to-severe COPD, 2MWDs are as informative as 6MWDswithout their disadvantages. Self-pacedwalks are as useful as
externallypaced Shuttles.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1462, available online athttp://www.sciencedirect.com
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The exercise capability of patients with chronic obstruc-
tive pulmonarydisease (COPD) is partly dictatedby psy-
chological factors, including motivation, and partly by
the pathophysiology of the disease. Respiratory me-
chanicsF airway function, inspiratorymuscle strength,
hyper-in£ation and the ventilatory pattern of the pa-
tients, all play their part. However, other factors, such
as ventilatorydrive, bloodgases, cardiac response, nutri-
tion and skeletal muscle strength, are also important. It
is not surprising, therefore, that changes in forced ex-
piratory volume in1s (FEV1) may not adequately re£ectReceived19 February 2002, accepted in revised form 27 September
2002.
Correspondence should be addressed to:Dr Noemi Eiser,University
Hospital Lewisham, LewishamHigh Street, London SE13 6LH,UK.
Fax: ++44 20 8333 3092; E-mail: noemi.eiser@uhl.nhs.ukthe potential bene¢ts of bronchodilator drugs in COPD
(1^3).
There is increasing awareness that simple walking
tests provide important information on disability which
cannot be obtained from spirometry, particularly in pa-
tientswithmore advanced disease.However, supervised
walking tests are potentially time-consuming for health
professionals and also tiring for patients. The original
proposal was to measure a 12-min walking distance
(12MWD), which was validated against the ‘‘gold stan-
dard’’ bicycle ergometry (4,5). Subsequently, the 6-min-
ute walking test (6MWD) became accepted as
‘‘standard’’ although there are only limited data concern-
ing its validity.There are even less data for shorter walks,
such as the 5 and 2-minute walking tests (5MWD,
2MWD) (6^8).
Self-paced walking tests depend on the motivation
and expectations of the patient. To circumvent this
408 RESPIRATORYMEDICINEproblem, the incremental shuttle walking test (Shuttle)
was recently introduced (9,10).This retains the simplicity
ofmeasuring distance achieved, while imposing an incre-
mental acceleration, pushing the patient to his/her limit.
This test has beenvalidated against a conventional tread-
mill test in a small number of patients with COPD (9).
In clinical practice, themost frequent need is for a re-
peatable test capable of assessing the patient’s baseline
exercise capacity and detecting any spontaneous or
treatment-induced change. The test should be neither
too tiring for the patient nor too time-consuming for
the investigator. It is not clear whether the 6MWD can
be further reduced or whether externally paced-walks
have advantages over self-pacedwalks.
The aim of the present study was to evaluate the role
of 2MWD in assessing bronchodilator (BD) responses of
patients with moderate-to-severe COPD, as de¢ned by
the European Respiratory Society criteria (11). First, we
assessed the reliability, repeatability and learning e¡ects
of 2MWDtests over 3 days.Then,we assessed the ability
of’2MWDs to detect BD e¡ect. The results were com-
pared with those of the 6MWD, the Shuttle and spiro-
metry.
METHODS
Patients
Fifty-seven patients (30males and 27 females) withmod-
erate-to-severe, but stable COPD, withmean age 6978
years (SD), participated in the study of reproducibility of
thewalking tests.Fifty-four of these patients performed
the study of the e¡ects of BDs on the walking tests.
Mean baseline and post-BD FEV1values were 0.921 (SD =
0.381) and1.151 (SD = 0.441), respectively, andmean base-
line FEV1was 35% predicted (SD = 13%). No patient had
restinghypoxaemia andnonehadhad a respiratory infec-
tion for at least1month prior to study. All withheld oral
and long acting BDs on the study days and inhaled BDs
for 12h prior to study. Inhaled and oral steroids were
continued in those patients taking them long-term.The
studieswere startedbetween1100 and1400h. Individuals
always started the tests at the same time on their di¡er-
ent study days and patients were asked to refrain from
eating for 2h before the tests. No patient had any con-
current diseases a¡ecting either their mobility or their
exercise tolerance and no patient had participated in
walking tests previously.
The subjects gave informed verbal consent to the
study, which was approved by the Guys and Lewisham
Hospitals Ethics Committee.
Measurements
Both 6MWD and 2MWDtestswereperformed along an
indoor circuit corridor measuring 120m, having 30-minrests between tests.The same investigator accompanied
the patient on all occasions, walking in front of the pa-
tient. Standardised encouragement was given to walk as
fast as possible and to restart if the patient stopped to
rest as recommended by Guyatt (12). Patients were dis-
couraged both from talking while they walked and from
sitting down to rest.
The incremental shuttle test was performed as de-
scribed by Singh et al.(9), walking up and down a 10-m
course around two cones at increasing speeds. The
speed of walking, increasing every minute, was dictated
by an audio signal played from a tape cassette.The num-
ber of10-m shuttles was recorded.
Immediately at the end of each exercise test, patients
were asked to score their post-exertional dyspnoea on a
Borg scale (13) and also on a100mmvisual analogue scale
(VAS), where 0 was no dyspnoea and 100mm was the
most severebreathlessness imaginable.The scalewas ex-
plained to thepatientbefore and at the end of eachwalk.
Patients were not allowed to see their previous scores
when deciding on the level of their dyspnoea.
FEV1, forced vital capacity (FVC) and slow vital capa-
city (SVC)weremeasuredwith a dry spirometer (Vitalo-
graph, Bucks, U.K.)Fthe best of three technically
satisfactorymeasurements was used.
Protocol for study days
Reproducibility
The major comparisons of the reproducibility of walks
were made when the patients were in a stable, post-BD
state in order to ensure thebest and ‘‘constant’’ baseline.
The walks were completed between 40 and120min fol-
lowing nebulised salbutamol 2.5mg with ipratropium
bromide 0.5mg (Combivent) when BD was expected to
bemaximal and stable.On 9 separate days, patients per-
formed three exercise tests with 30-min rests between
each test.On 3 days of consecutiveweeks, 2MWDwere
performed, on 3 days 6MWD and on 3 further days Shut-
tle tests. Altogether patients performed nine walks of
each type but not all of the 57 patients performed all
types of walking tests. There was random ordering of
type of walking test.
Sensitivity to change
The sensitivity to change of the lung function tests and
walking distance in these patientswas examined on 3 se-
parate days following the ¢rst part of the study; spiro-
metry and either of the 2MWD, 6MWD or Shuttle
were performed before and 40min after the same neb-
ulised BDs. All study days were completed within a 2-
month period.
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Restricted maximum likelihood estimation (REML) was
performed using Genstat 5 Release 3.1 (14) to estimate
the variance components between and within patients
for each exercise test. Each variance componentwas ex-
pressed as a percentage of the total variability (sum of
the two variance components).The reliability of the test
was calculated from the percentage of the total variabil-
ity due to variation between subjects. The repeatability
of the testwas calculated from thepercentage of the to-
tal variability due to variation within subjects. Visit (1,2
and 3), walk (1,2 and 3 on each visit) and their interaction
were included in the model as ¢xed e¡ects.Wald tests
were performed to assess whethermean values di¡ered
systematically between visits or betweenwalks.
Paired t-tests were used to assess the e¡ect of the
BDs on exercise capacity and spirometry. A sensitivity
index was calculated from mean change/standard devia-
tion of change in order to compare BD e¡ects directly.
RESULTS
Repeatedwalks (post-BD)
The mean post-BD FEV1 of the 57 patients who com-
pleted the nine 2MWD was 1.151 (range 0.40^2.161) and
themean 2MWDwas153m. In order to compare repro-
ducibility of the di¡erent types of walk, 23 of these pa-
tients also performed 6MWD and 25 also performed
Shuttles. The mean post-BD values were 428m for
6MWD and 27 Shuttles. It was not possible to compare
all types of walks in all 57 patients because some of them
developed acute exacerbations of their COPD and some
refused to attend on somany occasions.
Comparing mean values between visits or between
walks to assess any learning e¡ects, there was, on aver-
age, a signi¢cant trend for the distance to increase
fromwalk1towalk 3 for all three types of exercise tests
(Table1).However, after the ¢rst walk of each day, these
di¡erenceswere very small and therewas never a signi¢-
cant di¡erence between the second and third walk on
any day. There were also signi¢cant di¡erences in the
means among 3 days for all three types of exercise tests,
but there was no signi¢cant trend for distance to in-
crease or decrease with day. There were no systematic
changes for the dyspnoea scores. In general, the Borg
scorewasmore reproducible than theVAS score.
All exercise tolerance tests showedgoodreliability; at
least 90% of the variance was due to between patient
variation and less than 10% to within-patient variation
(Table 2). The 2MWD was the most reliable whilst the
Shuttle was the least reliable. Borg and VAS post-exer-
tional dyspnoea scores proved less repeatable than the
walking distances. Between 22% and 38% of their var-
iance was due to within-subject variability. Althoughthere was little di¡erence between the reliability of VAS
and Borg scale dyspnoea scores, these scoresweremost
reliable when scored after 2MWD and least reliable
when scored after Shuttle.
Walks before and after BDs
All improvements in 2MWD, 6MWD, Shuttle walks and
spirometry were highly signi¢cant (Table 3). Spirometry
was the most sensitive method of detecting BD, with
sensitivity indexes (SI) of 1.50SD, 1.60SD and 1.27SD, for
FEV1, FVC and SVC, respectively.The SIs for thewalking
tests were very similar; 6MWD was the most sensitive
with a mean SI of 0.84SD, the Shuttle intermediate (mean
SI = 0.76SD) and 2MWD was least sensitive (mean SI =
0.75SD). By contrast, SIs for post-exertional VAS dys-
pnoea scores were lower; for 6MWD, SI=0.64SD, for
2MWD SI=0.57SD and for Shuttle SI=0.30SD. Although
there were signi¢cant improvements in mean VAS dys-
pnoea scores for all three exercise tests, BDs failed to
produce statistically signi¢cant mean changes in Borg
dyspnoea scores for the 2MWD and Shuttle tests. Un-
fortunately, the relatively small numbers of patients pro-
viding BD responses with all three types of exercise
testing precluded calculation of meaningful correlations
between exercise tests.
DISCUSSION
This study has established acceptable reproducibility and
sensitivity to change of both self-pacedwalking tests and
the incremental Shuttle walk.The 2MWD compared fa-
vourably with themore traditional 6MWD and the new-
er, externally paced Shuttle walk, but repetitions of the
2MWD before and after therapeutic interventions are
less tiring than the other two types of walking tests.
Most commonly, the e¡ects of BDs in COPD patients
have been assessed on the basis of their acute e¡ects on
spirometry. However, there are many unresolved pro-
blems associated with these assessments. First, there is
still no general consensus for what constitutes a signi¢-
cant response. Then, substantial evidence suggests that
‘‘reversibility’’ is a continuous variable rather than a di-
chotomous trait (15^17) and so any cut-o¡ point is prob-
ably arbitrary (18). An additional confounding factor is
that methods of calculating BD responses (15,17^22) re-
main controversial. Furthermore, several studies have
shown that, not only does the reproducibility of these
responses vary over time (18,19,22^25), but also, that in
COPD patients, there is a poor correlation between the
acute lung function response to BDs and their e¡ect on
symptoms and quality of life (1,2,19,24,25).
TABLE 1. Meanvalues for eachwalkon each day fordistance and dyspnoea scoresF 2MWD (a),6MWD (b) and Incremental Shuttle (c)
Walk1 Walk 2 Walk 3 Day
mean
Walk1 Walk 2 Walk 3 Day
mean
Walk1 Walk 2 Walk 3 Day
mean
(a) 2MWD, n=57
Day1
(b) 6MMD n=23
Day1
(c) Shuttles n=25
Day1
2MWD (m) 152.7 155.5 157.2 155.1 6 MWD (m) 428 439 438 435 Shuttle (m) 270 284*** 292 282
VAS (mm) 42 41 45 43 VAS (mm) 39 41 37 39 VAS (mm) 40 40 41 40
Borg 3.5 3.4 3.6 3.5 Borg 3.7 3.8 3.7 3.7 Borg 3.6 3.9w 3.9 3.8
Day 2 Day 2 Day 2
2MWD (m) 157.3 159.6 160.9 159.3* 6MWD (m) 419 423 436 426* Shuttle (m) 289 298 297 295*
VAS (mm) 41 39 43 41 VAS (mm) 37 37 36 37 VAS (mm) 38 39 37 38
Borg 3.5 3.4 3.5 3.4 Borg 3.7 3.8 3.8 3.8 Borg 3.7 3.8 3.8 3.8
Day 3 Day 3 Day 3
2MMD (m) 155.7 157.8 159 157.5 6MWD (m) 432 436 433 434** Shuttle (m) 278 296*** 307 294
VAS (mm) 39 37 42 39 VAS (mm) 39 37 36 37 VAS (mm) 37 37 36 37
Borg 3.4 3.4 3.4 3.4 Borg 3.5 3.5 3.6 3.5w Borg 3.5 3.6 3.6 3.6
Walkmean Walk mean Walk mean
2MWD (m) 155.2 157.7** 159 157.3 6MWD (m) 426 433*** 436 432 Shuttle (m) 279 292** 298 290
VAS (mm) 41 39w 43 41 VAS (mm) 38 38 36 38 VAS (mm) 38 39 38 38
Borg 3.5 3.4 3.5 3.5 Borg 3.6 3.7 3.7 3.7 Borg 3.6 3.7 3.8 3.7
LSD dayor
walkmeans:
Distance=2.0m
VAS=2.5mm
Borg=0.2
LSDindividualmeans:
Distance=3.4m
VAS=4mm
Borg=0.4
LSD dayor
walkmeans:
Distance=7m
VAS=3.6mm
Borg=0.2
LSDindividualmeans:
Distance=12m
VAS=6mm
Borg=0.4
LSD dayor
walkmeans:
Shuttle (m)=10
VAS=3mm
Borg=0.2
LSDindividualmeans:
Shuttle (m)=11
VAS=6mm
Borg=0.3
(a) LSD least signi¢cant di¡erence between any pair of means: *signi¢cant di¡erence betweenmean 2MWD on Days1and 2; **signi¢cant di¡erence betweenmean ¢rst and second
2MWDonthe same day; wsigni¢cantdi¡erence betweenmeanVAS dyspnoea score on Days 2 and 3.
(b) LSDleast signi¢cantdi¡erencebetweenanypairofmeans: *signi¢cantdi¡erencebetweenmean 6MWDonDays1and 2; **signi¢cantdi¡erencebetweenmean 6MWDonDays 2 and
3; ***signi¢cantdi¡erence betweenmean ¢rst and second 6MWDonthe same day; wsigni¢cantdi¡erence betweenmean Borgdyspnoea score on Days 2 and 3.
(c) LSD least signi¢cant di¡erence between any pair of means: *signi¢cant di¡erence betweenmean Shuttles on Days1and 2; **signi¢cant di¡erence betweenmean ¢rst and second
Shuttles onthe same day; ***signi¢cantdi¡erencebetween ¢rst and second Shuttles on Days1and 3; wsigni¢cantdi¡erencebetweenmean Borgdyspnoea score onDay1between ¢rst
and secondwalk.
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TABLE 2. Variance components for the three types of walk fordistance and dyspnea scores
2MWD (n=57) 6 MWD (n=23) Shuttle (n=25)
Variance component % Total Variance component % Total Variance component % Total
Walking test
Betweenpatients 1468.0 94.9 4603.1 92.3 88.9 90.6
Within-patienterror 79.5 5.1 382.2 7.7 9.2 9.4
Total 1547.5 4985.3 98.1
VAS
Betweenpatients 436.5 76.7 263.6 71.7 150.3 61.7
Within-patienterror 132.7 23.3 104.1 28.3 93.2 38.3
Total 569.2 367.7 243.5
Borg
Betweenpatients 1.682 77.7 0.967 74.2 0.730 68.2
Within-patienterror 0.482 22.3 0.337 25.8 0.340 31.8
Total 2.164 1.304 1.070
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Similar criticisms can be levelled at exercise tests. Argu-
ments continue regarding the most appropriate form of
clinical testing for COPDFwhether self-paced or im-
posed pacing gives a more useful indication of practical
disability.There are few data concerning the methods of
quantifying response to treatment and no agreed de¢ni-
tion of a signi¢cantresponse to interventions.Neverthe-
less, results from a recent study suggest that, on
average, COPD patients are able to notice a change of
54m in a 6MWD (26).No similar information is available
for 2MWD or Shuttle.
Themeanwalking distances reported in our study are
in keeping with others studying COPD patients. For in-
stance, Guyatt (12) reported that in 43 patients with a
mean FEV1 of 0.971 (SD = 0.251), the 2MWD was 145^
155m and the 6MWD was 390^450m and Foglio (27)
found a mean 6MWD of 467m (SD = 61) in patients with
an FEV1 50% predicted normal. Similarly, in the small
group of COPD patients in Singh’s original paper (10) the
mean shuttle distances were 345^378m.
Some years ago, Leitch et al. (28) found that in COPD
patients, the 12MWD correlated better with symptoms
than did the FEV1 in patients with a rather restricted
range of FEV1. They suggested that walking distances
were a useful indicator of disability. A free self-paced
walk is more natural than either treadmill or bicycle er-
gometry and it canbeperformed anywhere,without ex-
pensive or complicated equipment. McGavin et al. (29)
reported that the results of the12MWD correlatedwell
with both VO2max and ventilation, measured during
treadmill exercise.They also found that the 2MWD cor-
relatedwithperceiveddyspnoea on a Borg scale.By con-
trast, Foglio et al. (27) reported that for shorter walks
(6MWD),VAS dyspnoea scores but not Borg scores cor-related with distance walked, maximum oxygen con-
sumption and with maximum work-load during bicycle
ergometry. 12MWD can be very tiring for patients and
are impracticable for routine use for reasons given ear-
lier. Shorter walking tests have many advantages but
have been inadequately validated to date.
Reproducibility of walking tests
There is evidence that the degree of encouragement gi-
ven to subjects in£uences the reproducibility of corridor
walking tests. Guyatt (12) obtained a mean 30.5m im-
provement during 6MWDs when a group of COPD pa-
tients were given verbal encouragement to continue
walking. A similar trend was found for 2MWD but it
was not statistically signi¢cant. In the present study, we
were careful both to standardise the encouragement gi-
ven and to ensure that the same investigator always ac-
companied the same patient. In addition, we gave the
patients a standardised dose of BDs before the walks
and performed the walks at times when the e¡ects of
the BDs were assumed to be on a plateau, in order to
minimise any variation in their functional state between
thewalks (30).Using thesemeasures, wehave found that
the self-pacedwalks are as reproducible as the externally
pacedwalks.
Previous studies have reported that both12MWD and
6MWD are reproducible, with an intra-subject coe⁄-
cient of variation of 5% on the same day (4% after two
practice walks) and of 8% between days (5,31,32). There
is also some evidence froma small, early studybyButland
et al. (6) that the 2MWD is probably reproducible after
two walks and that it correlates well with 6MWD and
12MWD. However, only four walks were repeated on 1
day and no statistical analysis was presented. In the pre-
TABLE 3. E¡ectof BDs on spirometry, walkingdistances and the dyspnoea scores
Baseline Post-BD Mean di¡erence P value SD Change as SD
Mean SD Mean SD
2MWD (m)
n=44
153 35 162 34 9 0.0001 0.75
VAS (mm) 45 25 35 21 10 0.001 0.57
Borg 3.4 1.4 3.1 1.2 0.4 0.08 0.47
6 MWD (m)
n=54
424 115 462 106 37 0.0001 0.84
VAS (mm) 60 23 49 23 11 0.0001 0.64
Borg 4.7 1.6 3.9 1.5 0.8 0.0001 0.68
Shuttle (n)
n=50
27 11 30 11 3 0.0001 0.76
VAS (mm) 51 20 47 22 4 o0.04 0.3
Borg 4.3 1 4.1 1 0.2 o0.07 0.27
Spirometry (i)
n=57
FEV1 0.92 0.38 1.15 0.44 0.23 0.0001 1.5
FVC 2.32 0.81 2.79 0.85 0.47 0.0001 1.6
SVC 2.54 0.89 2.89 0.89 0.35 0.0001 1.27
412 RESPIRATORYMEDICINEsent study, all threewalking tests demonstrated accepta-
ble reproducibilityFthe 2MWD showing the best re-
producibility. A small learning e¡ect was seen
consistentlybetween the ¢rst twowalks of each day dur-
ing all types of walking test.This is in general agreement
with earlier studies in which the increments in walking
distances persisted for only the ¢rst two or threewalks
(5,6,14,28) but is in contrast with signi¢cant learning ef-
fects over 12 5-min walks reported by Knox et al. (7).
The reason for this latter ¢nding is obscure.
There are less published data concerning the reprodu-
cibility of incremental Shuttle walking tests. However,
Singh (10) reported that there was a learning e¡ect
between Shuttles 1 and 2 but no signi¢cant di¡erence
between Shuttles 2 and 3 when the Shuttles were re-
peated on di¡erent days aweek apart in10 patients with
COPD. In this and two more recent studies, the Shuttle
correlated well with 6MWD in COPD patients, but, as
with other walking tests, there was a poor correlation
with lung function (10,33,34). Our study also showed
good repeatability of the incremental Shuttle test within
and between days. However, we did not attempt to
correlate the results with other types of walk because
of the relatively small numbers of patients studied.
Thus, this study shows that both the Shuttle and the
2MWD with standardised encouragement (from the
same investigator) are reproducible both within days
andwithup to 2-week intervals between testdays. After
one practice walk, they can be used with con¢dence to
assess patients’ exercise tolerance. Both are practical,
needing few facilities apart from adequate space forwalking.They are easy to perform for both patient and
assessor. The assessor needs relatively little trainingF
DW was a student of Fine Arts with only a few weeks
training in lung function andwalking tests.
Sensitivity to change
Althoughboth12MWDand6MWDimprove signi¢cantly
after BDs (15,25), thesewalking tests canbe tiring, parti-
cularly when repeated several times in the same day dur-
ing interventional studies. In the present study of
severely disabledpatients, the less tiring 2MWD and also
the Shuttle demonstrated highly signi¢cant improve-
ments after BDs.The sensitivities to changewere accep-
table, although not quite as good as for 6MWD. During
our study, the sensitivity tests were performed after the
reproducibility tests.Thus, there was no signi¢cant con-
foundingby learning e¡ects during the sensitivity testing.
However, should the walks be used before and after an
intervention in therapeutic trials, a practice walk is re-
commended. In this study no placebo was used since we
were comparing the e¡ects of an intervention on thedif-
ferent walking tests rather than investigating the e⁄-
cacy of the bronchodilators.Our study has not excluded
thepossibility that, for patientswho have less severe dis-
ease, the short 2MWDmay not be taxing enough to de-
tect change after a BD or other therapeutic
intervention. Patients with mild disability might be able
to complete the 2-min exercise before they become ex-
cessively breathless.
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Someyears ago Stark and colleagues (34,35) reported fa-
vourably on the sensitivity and repeatability of VAS dys-
pnoea scores butwe have previously found that they are
less reproducible thanwalking distances (36). In the pre-
sent study, the reproducibility of the Borg score was
somewhat better than VAS dyspnoea score. However,
these scores demonstrated little BD-induced change, ex-
cept following the 6MWD. As in previous studies, we
found that, despite repeated explanations, patients
found the VAS scale confusing and frequently asked the
investigators where to score on the line. Consequently,
we had much less con¢dence in the reliability of these
data than in the walking distances or the lung function
test results.
CONCLUSIONS
Both the 2MWD and shuttle walks are convenient, re-
producible and sensitive methods for assessing exercise
capacity of patients with moderate and severe COPD.
Neither VAS nor Borg post-exertional dyspnoea scores
add any valuable information.There is no important dif-
ference in either the reproducibility or sensitivity of self-
paced or externally pacedwalking tests.The 2MWDhas
the advantage of being the least tiring for severely dis-
abled patients. After one practice walk, it can be used
with con¢dence to assess exercise tolerance during ther-
apeutic trials in such patients.
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